Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

ts with metastatic breast cancer receiving chemotherapy when administered to target a hemoglobin of greater than 12 g/dL;

-- increased the risk of death when administered to target a hemoglobin of 12 g/dL in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for this population.

(See WARNINGS: Increased Mortality and/or Tumor Progression in the prescribing information).

The Aranesp prescribing information, including important safety information and boxed warning, may be accessed at www.aranesp.com.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2006, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/1/2008)...ecember 9 at 11:00 am ET to Discuss Phase 2 Study ... Calif., Dec. 1 Sunesi...armaceutical company focused on the development an...today announced new data from its studies of vorel...nted during the 50th American Society of Hematolog...
(Date:11/28/2008)...ire/ -- German biotech company,Partec is expandin...ing and,AIDS patient follow-up diagnostics for de..., 2.5 million patient tests have been performed wi...Flow" system, supporting already,more than 1 mill...on of the,Partec innovation, the average cost of ...
(Date:11/26/2008)...RANKLIN, Mass., Nov. 26 ...nced today that it has received full approval from...ts U.S. pivotal trial to study the effectiveness o...ted therapy in the prevention of Contrast-Induced ...d PLC,s request to expand their investigation from...
(Date:11/25/2008)...swire-FirstCall/ -- Poniard,Pharmaceuticals, Inc....cused on,innovative oncology therapies, announced...atives for its preclinical research programs in or...n the clinical development of picoplatin,its lea...mmercialization of,picoplatin in the treatment of...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3ExonHit Therapeutics 2007 Financial Results 3736 1ExonHit Therapeutics 2007 Financial Results 3736 2ExonHit Therapeutics 2007 Financial Results 3736 3ExonHit Therapeutics 2007 Financial Results 3736 4ExonHit Therapeutics 2007 Financial Results 3736 5ExonHit Therapeutics 2007 Financial Results 3736 6ExonHit Therapeutics 2007 Financial Results 3736 7ExonHit Therapeutics 2007 Financial Results 3736 8ExonHit Therapeutics 2007 Financial Results 3736 9ExonHit Therapeutics 2007 Financial Results 3736 10ExonHit Therapeutics 2007 Financial Results 3736 11ExonHit Therapeutics 2007 Financial Results 3736 12Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 1Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 2New Findings Support Alternatives to Pap Test 13540 1New Findings Support Alternatives to Pap Test 13540 2New Findings Support Alternatives to Pap Test 13540 3New Findings Support Alternatives to Pap Test 13540 4AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 1AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 2
(Date:12/2/2008)...RNewswire/ -- MedPro Imaging, a premier provider,...d the appointment of three,new ultrasound sales p...ve,expansion. The company also announced the rel...due to substantial growth throughout 2008. Keith,...nt of Sales and Marketing in,February of this yea...
(Date:12/2/2008)... keep driving safe, research shows , , T... on a cell phone are more distracted and more pron...d sitting next to them in the car, a new report fi...oint attention, so when you have a person sitting ...erson actually understands something about traffic...
(Date:12/2/2008)..., Kessler Foundation continues to improve the live...ST ORANGE, N.J.Dec. 2 One of the l... disabilities, Henry H. Kessler Foundation, announ...oundation. The Foundation is also changing the nam... Research Center and Kessler Foundation Program Ce...
(Date:12/2/2008)...lf Have Skipped Medical Care Due to Cost Issues- ,...swire/ -- A new survey released today by the Natio...hts another troubling aspect of the current financ...care for themselves or their families to save mone...ir health has gotten worse over the past five year...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4
...Carolina at Chapel Hill, in the current issue of P... may be possible molecular origin of at least nine... These neuro degenerative diseases, including Hunt...posit of proteins inside nerve cells. This deposit...
...logged arteries leading to a condition of early at...n the current issue of Psychosomatic Medicine. How...any such tendencies, said the study. The researche...and had found increased thickness of the lining of...
...he journal Antimicrobial Agents and Chemotherapy p...s that occur in the human saliva can lead to new w...y in children. Researchers at the University of Wa...ne a possible correlation between dental caries (t...
...l death for elderly people. A new study conducted ...s are four times more likely to fall than those wh...e are estimated to have type 2 diabetes, and the n... people by 2025. Previous investigations have def...
Other Medicine News:
Herpes Simplex Virus 2 IgG ELISA.
Cytomegalovirus IgM ELISA.
Small Incision Microforceps: Tano ILM Forceps
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling
Medicine Products: